Welcome to our dedicated page for POOLBEG PHARMA PLC news (Ticker: POLBF), a resource for investors and traders seeking the latest updates and insights on POOLBEG PHARMA PLC stock.
Poolbeg Pharma PLC (symbol: POLBF) is a biopharmaceutical company dedicated to developing and commercialising innovative medicines focused on diseases with significant unmet medical needs. Led by an experienced team, including the recent addition of members from Amryt Pharma plc, the company is committed to delivering value to shareholders. Poolbeg's clinical programs target large markets such as cancer immunotherapy-induced CRS, infectious diseases, and metabolic conditions like obesity, with the development of an oral GLP-1R agonist. The company utilizes a cost-effective development strategy to produce high-quality human data supporting partnerships and future development.
Rhea-AI Summary
Poolbeg Pharma (POLB) announces the acceptance of an abstract highlighting the potential of POLB 001 as a groundbreaking therapy at the 18th International Congress of Immunology. POLB 001 is a potential treatment of severe influenza and Cytokine Release Syndrome (CRS) associated with cancer immunotherapies. The poster presentation will discuss POLB 001's positive LPS human challenge trial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) announces the appointment of key former executives of Amryt Pharma plc to its leadership team. David Allmond, John McEvoy, and Laura Maher will join Poolbeg, enhancing the Company's expertise and capabilities. Allmond will become Chief Business Officer, McEvoy will be SVP, Chief Legal Officer, and Maher will assume the role of Vice President of Clinical Operations. The appointments aim to accelerate Poolbeg's strategy of developing exciting clinical assets and acquiring approved and marketed drugs to generate revenue and fund innovative product development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Poolbeg Pharma announces that an abstract detailing POLB 001's promise as a potential treatment for Cytokine Release Syndrome associated with cancer immunotherapies has been accepted for presentation at the 65th American Society of Hematology Annual Meeting and Exposition. The presentation will provide insight into the results obtained from the POLB 001 LPS human challenge trial, highlighting its potential use in the treatment of CRS. An effective therapy for CRS associated with cancer immunotherapies has the potential to make these treatments more tolerable and widely accessible.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) will host a meeting on November 6, 2023, to provide an update on its POLB 001 Oncology Programme. The program targets Cytokine Release Syndrome (CRS) associated with cancer immunotherapy treatments. Severe cases of CRS can be life-threatening, and an effective treatment could make these therapies more accessible and reduce side effects. The meeting will feature presentations from key opinion leaders and a patient advocate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Poolbeg Pharma partners with a Nasdaq-listed biopharma company for the development of an optimised oral drug to treat a metabolic condition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Positive Conclusion Reached in Immunomodulator I Patent Opposition
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Poolbeg Pharma announces withdrawal of opposition to its European patent, strengthening its intellectual property portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Poolbeg Pharma announces unaudited interim results, strong cash balance of £14.1 million as of June 30, 2023. Positive results from POLB 001 trial, potential treatment for severe influenza. Strategic expansion into oncology. AI programme with CytoReason identifies valuable drug targets. Progress on RSV drug targets and treatments. Oral Vaccine consortium progresses to next phase. Continued progress on GLP-1 agonist trial. Professor Brendan Buckley appointed as Non-Executive Director. CEO highlights significant progress and future growth. Investor presentation scheduled. Change of name for Nominated Adviser and Joint Broker.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of POOLBEG PHARMA PLC (POLBF)?
The current stock price of POOLBEG PHARMA PLC (POLBF) is $0.151 as of September 17, 2024.
What is the market cap of POOLBEG PHARMA PLC (POLBF)?
The market cap of POOLBEG PHARMA PLC (POLBF) is approximately 75.5M.
What is Poolbeg Pharma PLC focused on?
Poolbeg Pharma PLC focuses on developing and commercialising innovative medicines targeting diseases with a high unmet medical need.
Who leads Poolbeg Pharma PLC?
Poolbeg Pharma PLC is led by an experienced leadership team, including former members of Amryt Pharma plc.
What are the key areas of focus for Poolbeg's clinical programs?
Poolbeg's clinical programs target large addressable markets including cancer immunotherapy-induced CRS, infectious disease, and metabolic conditions like obesity.
What is Poolbeg's development strategy?
Poolbeg uses a cost-effective development philosophy to generate high-quality human data supporting partnering and further development.
What recent announcement has Poolbeg Pharma PLC made?
Poolbeg Pharma PLC has received notification of the Executive Chairman's purchase of ordinary shares, strengthening the company's position.
What intellectual property advancements has Poolbeg made?
Poolbeg Pharma PLC has recently been granted a significant patent related to its Immunomodulator II, further strengthening its robust intellectual property portfolio.
What strategic agreement has Poolbeg entered into?
Poolbeg Pharma PLC has entered into an exclusive option agreement to acquire an orphan drug candidate for Behçet's Disease.
What is the focus of Poolbeg's option agreement?
The exclusive option agreement is for a novel topical muco-adherent formulation of Pentoxifylline (tPTX) for the treatment of oral ulcers in patients with Behçet's Disease.
What market opportunity does Poolbeg target?
Poolbeg Pharma PLC aims to address market opportunities exceeding US$10 billion, particularly in cancer immunotherapy-induced CRS.
What recent patent grant has Poolbeg received?
Poolbeg Pharma PLC has received a fully granted patent from the US Patent Office for its Immunomodulator II patent application.
POOLBEG PHARMA PLC